
Kinoxis Therapeutics Pty Ltd
About
Kinoxis Therapeutics Pty Ltd is a private, Australian-based, clinical-stage biotechnology company developing first-in-class therapeutics to address the escalating demand for safe and effective treatments for behavioural and psychological symptoms in neuropsychiatric disorders. Kinoxis’ lead candidate, KNX100, is being developed for the treatment of behavioural and psychological symptoms in neuropsychiatric disorders, including agitation and aggression in dementia, and several substance use disorders. KNX100 has a novel mechanism of action, interacting with disease relevant pharmacological, molecular, and neural targets, to modify the dysregulated brain systems linked with specific behavioural and psychological symptoms in neuropsychiatric disorders. The compound has an extensive pre-clinical data package consisting of multiple cross-species animal efficacy models conducted across several independent research organisations. Kinoxis has completed a Phase 1 study conducted under a US IND and have demonstrated KNX100 to be safe and tolerable in healthy volunteers. Currently, KNX100 is being investigated in the CARES-X Phase 2 clinical trial, a multi-site study in Australia focused exploring its safety, tolerability, and efficacy as a treatment for agitation in dementia. Kinoxis is also advancing clinical programs targeting stimulant, opioid, and alcohol use disorders. Notably, the alcohol use disorder program is being developed in collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), while the opioid use disorder program has received significant funding from the US National Institute of Health/National Institute on Drug Abuse (NIH/NIDA). In addition to the KNX100 program, Kinoxis have a strategic partnership and licensing agreement with Boehringer Ingelheim to develop first-in-class oxytocin receptor targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders.
AU
Melbourne, Victoria
3000
Privately Held
18
Biotechnology Research
Top Decision Makers · 3
Chief Executive Officer

Hugh Alsop
Australia
******@***.com
Phone
(**) *** ****
Director, Drug Discovery
James Daniel, PhD
Australia
******@***.com
Phone
(**) *** ****
VP, Discovery Research
Tristan Reekie
Australia
******@***.com
Phone
(**) *** ****
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles

Find Emails
Access verified email addresses for your target contacts.
657M+ emails

Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers

More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.

